Leonard Braden Michael 4
4 · AN2 Therapeutics, Inc. · Filed May 30, 2025
Insider Transaction Report
Form 4
Leonard Braden Michael
10% Owner
Transactions
- Sale
Common Stock
2025-05-28$1.16/sh−2,000,000$2,320,000→ 3,749,432 total(indirect: Holding of BML Investment Partners, L.P.) - Sale
Common Stock
2025-05-30$1.03/sh−7,000$7,227→ 3,217,432 total(indirect: Holding of BML Investment Partners, L.P.) - Sale
Common Stock
2025-05-30$1.01/sh−425,000$429,250→ 3,224,432 total(indirect: Holding of BML Investment Partners, L.P.) - Sale
Common Stock
2025-05-28$1.16/sh−100,000$116,000→ 3,649,432 total(indirect: Holding of BML Investment Partners, L.P.)
Footnotes (2)
- [F1]BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
- [F2]The shares were sold in multiple transactions at an average price of $1.0324.